Hannah Asperger

Ms. Hannah Asperger

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HAHannah Asperger
Hannah Asperger
NSNadia Stamm
Nadia Stamm
BGBerthold Gierke
Berthold Gierke
Michal PawlakMichal Pawlak
Michal Pawlak
UHUte Hofmann
Ute Hofmann
MLMarina Ludescher
Marina Ludescher
Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breast carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor progression. The aim of our study was to investigate the involvement of PGRMC1 in cholesterol metabolism to detect new mechanisms by which PGRMC1 can increase lipid metabolism and alter cancer-related signaling pathways leading to breast cancer progression. Methods: The effect of PGRMC1 overexpression and silencing on cellular proliferation was examined in vitro and in a xenograft mouse model. Next, we investigated the interaction of PGRMC1 with enzymes involved in the cholesterol synthesis pathway such as CYP51, FDFT1, and SCD1. Further, the impact of PGRMC1 expression on lipid levels and expression of enzymes involved in lipid homeostasis was examined. Additionally, we assessed the role of PGRMC1 in key cancer-related signaling pathways including EGFR/HER2 and ERα signaling. Results: Overexpression of PGRMC1 resulted in significantly enhanced proliferation. PGRMC1 interacted with key enzymes of the cholesterol synthesis pathway, alters the expression of proteins, and results in increased lipid levels. PGRMC1 also influenced lipid raft formation leading to altered expression of growth receptors in membranes of breast cancer cells. Analysis of activation of proteins revealed facilitated ERα and EGFR activation and downstream signaling dependent on PGRMC1 overexpression in hormone receptor-positive breast cancer cells. Depletion of cholesterol and fatty acids induced by statins reversed this growth benefit. Conclusion: PGRMC1 may mediate proliferation and progression of breast cancer cells potentially by altering lipid metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as EGFR signaling. Our present study underlines the potential of PGRMC1 as a target for anti-cancer therapy.

29 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AFAndré Franken
André Franken
BBBianca Behrens
Bianca Behrens
FRFlorian Reinhardt
Florian Reinhardt
LYLiwen Yang
Liwen Yang
MRMahdi Rivandi
Mahdi Rivandi
HNHans Neubauer
Hans Neubauer
Background: The analysis of liquid biopsies, e.g., circulating tumor cells (CTCs) is an appealing diagnostic concept for targeted therapy selection. In this proof-of-concept study, we aimed to perform multiparametric analyses of CTCs to select targeted therapies for metastatic breast cancer patients. Methods: First, CTCs of five metastatic breast cancer patients were analyzed by whole exome sequencing (WES). Based on the results, one patient was selected and monitored by longitudinal and multiparametric liquid biopsy analyses over more than three years, including WES, RNA profiling, and in vitro drug testing of CTCs. Results: Mutations addressable by targeted therapies were detected in all patients, including mutations that were not detected in biopsies of the primary tumor. For the index patient, the clonal evolution of the tumor cells was retraced and resistance mechanisms were identified. The AKT1 E17K mutation was uncovered as the driver of the metastatic process. Drug testing on the patient’s CTCs confirmed the efficacy of drugs targeting the AKT1 pathway. During a targeted therapy chosen based on the CTC characterization and including the mTOR inhibitor everolimus, CTC numbers dropped by 97.3% and the disease remained stable as determined by computer tomography/magnetic resonance imaging. Conclusion: These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.

1 August 2021 in Translational Oncology
Verified
Journal Article
Open access
HAHannah Asperger
Hannah Asperger
JCJan-Philipp Cieslik
Jan-Philipp Cieslik
BAB. Alberter
B. Alberter
CKC. Köstler
C. Köstler
BPBernhard Michael Polzer
Bernhard Michael Polzer
HNHans Neubauer
Hans Neubauer
Liquid Biopsy (LB) in the form of e.g., circulating tumor cells (CTCs) is a promising non-invasive approach to support current therapeutic cancer management. However, the proof of clinical utility of CTCs in informing therapeutic decision-making for e.g., breast cancer in clinical trials and associated translational research projects is facing the issues of low CTC positivity rates and low CTC numbers - even in the metastasized situation. To compensate for this dilemma, clinical CTC trials are designed as large multicenter endeavors with decentralized sample collection, processing and storage of products, making data management highly important to enable high-quality translational CTC research. In the DETECT clinical CTC trials we aimed at developing a custom-made, browser-based virtual database to harmonize and organize both decentralized processing and storage of LB specimens and to enable the collection of clinically meaningful LB sample. ViBiBa processes data from various sources, harmonizes the data and creates an easily searchable multilayered database. An open-source virtual bio-banking web-application termed ViBiBa was created, which automatically processes data from multiple non-standardized sources. These data are automatically checked and merged into one centralized databank and are providing the opportunity to extract clinically relevant patient cohorts and CTC sample collections. ViBiBa, which is a highly flexible tool that allows for decentralized sample storage of liquid biopsy specimens, facilitates a solution which promotes collaboration in a user-friendly, federalist and highly structured way. The source code is available under the MIT license from https://vibiba.com or https://github.com/asperciesl/ViBiBa.

1 January 2026 in Stroke: Vascular and Interventional Neurology
Verified
Journal Article
Open access
HAHannah Asperger
Hannah Asperger
FBFelix Bode
Felix Bode
TETaraneh Ebrahimi
Taraneh Ebrahimi
CKChristine Kindler
Christine Kindler
JLJulia Layer
Julia Layer
HZH. Zimmermann
H. Zimmermann
BACKGROUND: Patients with severe prestroke disability (PSD) remain underrepresented in mechanical thrombectomy studies, despite their growing relevance in aging populations. This study used data from the German Stroke Registry-Endovascular Treatment to evaluate functional recovery, mortality, and poststroke care outcomes in this high-risk population. METHODS: We analyzed 9456 mechanical thrombectomy–treated patients with stroke from the German Stroke Registry-Endovascular Treatment (2015–2021), categorized by premorbid modified Rankin Scale (mRS): no PSD (mRS score, 0–1), moderate PSD (mPSD; mRS score, 2–3), and severe PSD (sPSD; mRS score, 4–5). Favorable outcomes were defined as an mRS score of 0 to 2 or return to baseline. Logistic regression adjusted for age, National Institutes of Health Stroke Scale, intravenous thrombolysis, reperfusion success, and sex was used to predict outcomes. A neural network subsequently explored feature importance. RESULTS: Among 9456 patients, 7387 had no PSD, 1648 mPSD, and 421 sPSD. Unadjusted 90-day outcomes showed increasing mortality with PSD severity and fewer favorable outcomes in both PSD groups. At 90 days, favorable outcomes occurred in 3020 patients without PSD (40.9%), 232 with mPSD (14.1%), and 85 with sPSD (20.2%). After adjustment, only mPSD was associated with lower odds of favorable outcomes, while both mPSD and sPSD remained independent predictors of higher mortality. Complication rates were similar across groups, except for higher vasospasm in patients without PSD. Including rebalanced sPSD samples in predictive models resulted in minor performance improvements but notable shifts in feature importance, with age and Alberta Stroke Program Early Computed Tomography Score emerging as key predictors, National Institutes of Health Stroke Scale decreasing in relevance, and factors such as local anesthesia and occlusion location becoming more prominent. CONCLUSIONS: Despite higher mortality, approximately a fifth of patients with PSD achieved favorable outcomes, suggesting that this group should not be routinely excluded from mechanical thrombectomy. Further studies should refine patient selection criteria and outcome definitions for this vulnerable population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03356392.

9 June 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
OSOmid Shirvani
Omid Shirvani
FBFelix J. Bode
Felix J. Bode
SSSebastian Stösser
Sebastian Stösser
HAHannah Asperger
Hannah Asperger
TETaraneh Ebrahimi
Taraneh Ebrahimi
JWJohannes Weller
Johannes Weller
ObjectivesThe HERMES-24 score recently demonstrated high accuracy for outcome prediction after large vessel occlusion (LVO) treatment in late time window patients from randomized clinical trials. I...

2 November 2026 in European Stroke Journal
Verified
Journal Article
Open access
HAHannah Asperger
Hannah Asperger
FBFelix J Bode
Felix J Bode
TETaraneh Ebrahimi
Taraneh Ebrahimi
LKLara Klehr
Lara Klehr
JLJulia Layer
Julia Layer
JWJohannes Weller
Johannes Weller
Introduction: Endovascular thrombectomy (EVT) is established for large infarcts, but remains cautiously applied in extensive infarcts with an Alberta Stroke Program Early CT Score (ASPECTS) of 0–2. Real-life outcome data remain limited. Patients and methods: Retrospective analysis of the German Stroke Registry-Endovascular Treatment comparing extensive (ASPECTS 0–2) and large infarcts (ASPECTS 3–5) in patients with anterior-circulation occlusion and EVT. The primary outcome was the ordinal 90-day mRS distribution; secondary outcomes were mRS 0–3, survival, quality of life (3-level European Quality of Life-5 Dimensions) and living condition. Results: Of 18,069 screened patients, 889 were analysed (ASPECTS 1–2, n = 89; ASPECTS 3–5, n = 800); none had ASPECTS 0. With ASPECTS 1–2, 20.2% achieved mRS 0–3 and 55.1% died within 90 days. In the model including successful reperfusion, no statistically significant association was detected between infarct group and the 90-day mRS distribution (common odds ratio [cOR] 0.80; 95% CI, 0.53–1.23) or mRS 0–3 (adjusted odds ratio [aOR] 0.89; 95% CI, 0.64–1.25), whereas successful reperfusion was associated with both (cOR 3.68; 95% CI, 2.31–5.85 and aOR 4.10; 95% CI, 2.45–6.86). Among survivors, median European Quality of Life-5 Dimensions utility index was 0.445 vs 0.541 (n = 27/324), and 51.5% vs 50.9% lived at home (n = 33/411). Discussion: An extensive infarct carried a challenging prognosis, yet acceptable outcome and non-institutional living remained achievable in a relevant minority. An independent association of infarct group with outcome was not detected. Conclusion: An acceptable outcome remained attainable in selected patients with extensive infarction, particularly after successful reperfusion. Lacking a medically managed comparator, these data describe prognosis rather than treatment effect.